| abstract |
PURPOSE: To provide an excellent transnasal calcitonin agent containing calcitonin as an active component in combination with a specific absorbefacient. n CONSTITUTION: A pharmaceutical composition for intranasal administration can be produced by using calcitonin as an active component, adding one or more absorbefacients selected from benzyl alcohol, ethanol, thiamine or its salt, salicylic acid or its salt,s capric acid or its salt, macrogol 400, pyridoxal or its salt, malic acid or its salt and pyrophosphoric acid or its salt, and mixing or impregnating the above components in a liquid diluent or a carrier suitable for the application to the nasal mucosa. The agent is used as an aqueous solution, hydrogel or solid powder. The amount of calcitonin is 200W6,000IU/ml, preferably 500W2,000IU/ml in the case of aqueous solution. It is administered preferably at a dose of 0.05W0.2ml and 1W5 doses daily by dripping or spraying into the nasal cavity. n COPYRIGHT: (C)1986,JPO&Japio |